TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37347913
Drug: In-person cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-person cognitive behavioral treatment
Study: 37348019
Drug: Standard endocrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard endocrine treatment of physician's choice (TPC)
Study: 37348272
Drug: Prescription of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription of optimal cardioprotective therapy at discharge
Study: 37348348
Drug: 2-year icotinib
Normalized name: nicotine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-year icotinib (125 mg thrice daily)
Study: 37348348
Drug: 1-year icotinib
Normalized name: nicotine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-year icotinib (125 mg thrice daily)
Study: 37348519
Drug: Omicron BA.1
Normalized name: COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine Product, Pfizer-BioNTech
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omicron BA.1 monovalent booster (50 μg)
Study: 37348519
Drug: Omicron BA.1
Normalized name: COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine Product, Pfizer-BioNTech
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omicron BA.1 bivalent booster (50 μg)
Study: 37348816
Drug: Intravenous ferumoxytol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ferumoxytol (2 infusions of 510 mg approximately 7 days apart)
Study: 37348817
Drug: Intravenous ferumoxytol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ferumoxytol (2 infusions of 510 mg)
Study: 37348817
Drug: Oral ferrous
Normalized name: ferrous fumarate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ferrous sulfate (325 mg twice daily)
Study: 37349100
Drug: Pembrolizumab (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (4 mg/kg)
Study: 37349318
Drug: Nivolumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab plus concurrent chemoradiotherapy (CRT)
Study: 37349747
Drug: Dentist-administered cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dentist-administered cognitive behavioural therapy (D-CBT, n=36)
Study: 37349841
Drug: Pregabalin 25
Normalized name: pregabalin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 25 mg
Study: 37350404
Drug: Post-extraction intravenous
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-extraction intravenous antibiotics
Study: 37350404
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy duration
Study: 37350492
Drug: High-sensitivity cardiac
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-sensitivity cardiac troponin I measurement at presentation, threshold of 2 ng/L
Study: 37350492
Drug: High-sensitivity cardiac
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-sensitivity cardiac troponin I measurement at presentation, threshold of 5 ng/L
Study: 37462028
Drug: Mechanical thrombectomy
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical thrombectomy (MT) plus best medical treatment (BMT)
Study: 37350968
Drug: Atezolizumab with
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab with EC/EP for two cycles followed by concurrent palliative HFRT and two cycles of atezolizumab with EC/EP, then atezolizumab every 3 weeks for a maximum of 2 years.
Study: 37350968
Drug: Concurrent hypofractionated
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent hypofractionated thoracic radiotherapy (HFRT) with immunochemotherapy.
Study: 37350989
Drug: Nangibotide (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nangibotide (1.0 mg/kg/h)
Study: 37350990
Drug: Weight-adjusted intermediate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-adjusted intermediate dose of low-molecular-weight heparin
Study: 37350990
Drug: Fixed-dose of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose of low-molecular-weight heparin
Study: 37351456
Drug: Adintrevimab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adintrevimab (300 mg, single intramuscular injection)
Study: 37351564
Drug: Orforglipron (12,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orforglipron (12, 24, 36, or 45 mg)
Study: 37351585
Drug: Antidepressant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant treatment (12 weeks acute phase and 16 weeks continuation phase)
Study: 37351932
Drug: Guided Imagery
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided Imagery (GI) treatment delivered via telephone for smoking cessation.
Study: 37351932
Drug: Standard evidence-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard evidence-based behavioral treatment delivered via telephone.
Study: 37352262
Drug: Tacrolimus/reduced-dose methotrexate/mycophenolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus/reduced-dose methotrexate/mycophenolate (mini-MTX/MMF)
Study: 37352266
Drug: Nivolumab 240
Normalized name: nivolumab 240 MG in 24 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 240 mg and brentuximab vedotin (BV) 1.8 mg/kg once every 3 weeks until disease progression or unacceptable toxicity.
Study: 37352284
Drug: Structured Emotionally
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured Emotionally Focused Family Therapy (EFFT)
Study: 37352322
Drug: Nifurtimox 60-day
Normalized name: nifurtimox
DrugBank: Nifurtimox (DB11820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifurtimox 60-day treatment regimen
Study: 37352322
Drug: Nifurtimox 30-day
Normalized name: nifurtimox 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifurtimox 30-day treatment regimen
Study: 37352498
Drug: pomalidomide 5
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: pomalidomide 5 mg orally for 21 days of 28-day cycles for up to 1 year
Study: 37353277
Drug: Continue disease-modifying
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continue disease-modifying therapy
Study: 37353277
Drug: Discontinue disease-modifying
Normalized name: Entex HC Discontinued
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinue disease-modifying therapy
Study: 37353278
Drug: Descartes-08 (autologous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Descartes-08 (autologous anti-BCMA rCAR-T therapy)
Study: 37353450
Drug: HepB-CpG vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HepB-CpG vaccine
Study: 37353654
Drug: Endoscopic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic treatment timing
Study: 37353788
Drug: Tumour necrosis
Normalized name: Tumour necrosis factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumour necrosis factor inhibitor (TNFi)
Study: 37353795
Drug: Remotely delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remotely delivered TEACH program plus treatment as usual (TAU)
Study: 37354546
Drug: Bempedoic acid,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bempedoic acid, 180 mg daily (n=2100)
Study: 37354554
Drug: 8 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 weeks of daily low-dose hCG (260 IU recombinant hCG) administration before IVF/ICSI cycle
Study: 37354976
Drug: Lactase nonpersistent
Normalized name: Lactase
DrugBank: Tilactase (DB13761)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactase nonpersistent (LNP) individuals consuming more than 12.46 g/d
Study: 37355035
Drug: Technology-assisted intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Technology-assisted intervention (12-week program including 3 center-based supervised exercise sessions, a fitness watch, 6 educational videos, and weekly video calls)
Study: 37355043
Drug: efinopegdutide 10
Normalized name: Efinopegdutide
DrugBank: Efinopegdutide (DB15077)
Approvals — FDA: no, EMA: no, PMDA: no
Description: efinopegdutide 10 mg weekly
Study: 37355043
Drug: semaglutide 1
Normalized name: semaglutide 14 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: semaglutide 1 mg weekly
Study: 37355263
Drug: Multimodal occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal occupational therapy including patient education, hand exercises, assistive devices and orthoses (n=90)
Study: 37355267
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment - identical-looking cuff placed around the arm but not inflated.
Study: 37356033
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg pegozafermin weekly
Study: 37356033
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg pegozafermin weekly
Study: 37356033
Drug: 44 mg
Normalized name: caffeine 44 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 44 mg pegozafermin once every 2 weeks
Study: 37356038
Drug: Crizanlizumab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crizanlizumab (5 mg/kg) plus standard of care
Study: 37356066
Drug: Combined clinically
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined clinically significant or severe hypoglycemia with insulin icodec
Study: 37356066
Drug: Combined clinically
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined clinically significant or severe hypoglycemia with insulin glargine U100
Study: 37356078
Drug: Ripretinib as
Normalized name: Ripretinib
DrugBank: Ripretinib (DB14840)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ripretinib as a fourth-line treatment
Study: 37356561
Drug: Lozenge containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lozenge containing Lacticaseibacillus rhamnosus, LGG® (DSM33156), Lactobacillus paracasei subsp. paracasei, L. CASEI 431® (DSM33451) and prebiotic (arginine 2%)
Study: 37356561
Drug: Placebo lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo lozenge without arginine or probiotics
Study: 37356618
Drug: Impact on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Impact on daily life
Study: 37356632
Drug: Topical tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical tranexamic acid (TXA) application, 1.25 g of TXA powder sprayed endoscopically on the ulcer, alongside 3 days of high-dose (8 mg/h) continuous infusion proton pump inhibitor therapy.
Study: 37356632
Drug: Standard group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard group (no TXA), alongside 3 days of high-dose (8 mg/h) continuous infusion proton pump inhibitor therapy.
Study: 37356632
Drug: Topical tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical tranexamic acid (TXA) application
Study: 37356634
Drug: US capsule
Normalized name: DIM-plus Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: US capsule endoscopy (USCE)
Study: 37356708
Drug: 15 mL
Normalized name: ethanol 0.15 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mL ExoFlo
Study: 37356876
Drug: Faster aspart
Normalized name: aspartate
DrugBank: Potassium aspartate (DB15819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faster aspart insulin
Study: 37357331
Drug: Camelina enriched
Normalized name: Camelina sativa seed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camelina enriched crackers (35 g, twice daily for 12 weeks)
Study: 37357331
Drug: Placebo crackers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo crackers (35 g, twice daily for 12 weeks)
Study: 37357807
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg iron supplements taken in the morning with ascorbic acid (AA)
Study: 37357807
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg iron supplements taken at different times of day without ascorbic acid (AA)
Study: 37357904
Drug: Ivermectin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (200 µg/kg) and Albendazole (400 mg)
Study: 37357904
Drug: Albendazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (400 mg) and Placebo
Study: 37357950
Drug: barecetamab monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: barecetamab monotherapy at 20 mg/kg IV every 3 weeks
Study: 37357950
Drug: barecetamab (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: barecetamab (20 mg/kg IV) and cetuximab (400 mg/m2) combination therapy
Study: 37357950
Drug: barecetamab at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: barecetamab at 1, 3, 5, 10, and 20 mg/kg IV on days 1 and 28 and weekly
Study: 37358545
Drug: Oral alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral alcohol challenge
Study: 37358640
Drug: Idelalisib containing
Normalized name: Idelalisib
DrugBank: Idelalisib (DB09054)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Idelalisib containing therapy
Study: 37358640
Drug: Idelalisib after
Normalized name: Idelalisib
DrugBank: Idelalisib (DB09054)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Idelalisib after prior ibrutinib therapy
Study: 37358640
Drug: Idelalisib without
Normalized name: Idelalisib
DrugBank: Idelalisib (DB09054)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Idelalisib without prior ibrutinib therapy
Study: 37358858
Drug: Standard-course therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-course therapy (another 5 days of antimicrobials)
Study: 37358858
Drug: Short-course therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course therapy (5 days of placebo)
Study: 37358858
Drug: Short-course therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course therapy
Study: 37358858
Drug: Standard-course therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-course therapy and Short-course therapy
Study: 37358916
Drug: IBI112 (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI112 (subcutaneous 5-600 mg or intravenous 100 and 600 mg)
Study: 37359242
Drug: Sotrastaurin 300
Normalized name: Sotrastaurin
DrugBank: Sotrastaurin (DB12369)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotrastaurin 300 mg and Binimetinib 30 mg
Study: 37359242
Drug: Sotrastaurin 200
Normalized name: Sotrastaurin
DrugBank: Sotrastaurin (DB12369)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotrastaurin 200 mg and Binimetinib 45 mg
Study: 37360346
Drug: Antioxidant treatment
Normalized name: OCTINOXATE 6 g in 100 g / AVOBENZONE 1.7 g in 100 g TOPICAL CREAM [Renewing Antioxidant Treatment SPF 6 GNLD International]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant treatment with lipoic acid
Study: 37360352
Drug: DOSE protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: DOSE protocol (higher intensity walking)
Study: 37360811
Drug: Low-intensity general
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity general fitness training sessions (twice a week for four weeks)
Study: 37360864
Drug: Convidecia (heterologous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convidecia (heterologous third dose)
Study: 37360864
Drug: Convidecia (heterologous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convidecia (heterologous second dose)
Study: 37360864
Drug: CoronaVac (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoronaVac (three doses)
Study: 37360864
Drug: CoronaVac (second
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoronaVac (second dose)
Study: 37549680
Drug: CoronaVac (third
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoronaVac (third dose)
Study: 37361483
Drug: Psychophysiologic symptom
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychophysiologic symptom relief therapy (PSRT) during a 13 week (approximately 44 hour) course.
Study: 37363967
Drug: Laxative use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laxative use
Study: 37363967
Drug: No laxative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No laxative use
Study: 37363965
Drug: Tucatinib, Letrozole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tucatinib, Letrozole, and Palbociclib (TLP combination)
Study: 37363992
Drug: Dostarlimab 500
Normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dostarlimab 500 mg every 3 weeks for four cycles, then 1,000 mg every 6 weeks until progression
Study: 37364000
Drug: Androgen receptor
Normalized name: Androgen receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen receptor pathway inhibitors (ARPI; e.g., enzalutamide, abiraterone acetate)
Study: 37364000
Drug: Androgen receptor
Normalized name: Androgen receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen receptor pathway inhibitors (ARPI)
Study: 37364033
Drug: Usual Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual Care Physical Therapy
Study: 37364220
Drug: Aspirin treatment
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin treatment for high-risk colorectal cancer
Study: 37364590
Drug: CagriSema (cagrilintide
Approvals — FDA: no, EMA: no, PMDA: no
Description: CagriSema (cagrilintide 2·4 mg + semaglutide 2·4 mg)
Study: 37364590
Drug: semaglutide (2·4
Approvals — FDA: no, EMA: no, PMDA: no
Description: semaglutide (2·4 mg)
Study: 37364590
Drug: cagrilintide (2·4
Approvals — FDA: no, EMA: no, PMDA: no
Description: cagrilintide (2·4 mg)
Study: 37364683
Drug: 20-mg/d lutein
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-mg/d lutein supplementation
Study: 37364685
Drug: HYP-CT (Hypnosis-enhanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: HYP-CT (Hypnosis-enhanced cognitive therapy)
Study: 37364710
Drug: Ecnoglutide (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ecnoglutide (subcutaneous injection)
Study: 37365046
Drug: Home Blood
Normalized name: LifeSource Aneroid Home Blood Pressure Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home Blood Pressure Monitoring (HBPM) combined with Collaborative Drug Therapy Management (CDTM)
Study: 37365210
Drug: Tablet-based system
Normalized name: BAKING POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet-based system combining structured symptoms questionnaire and 2-handed spiral drawing
Study: 37365557
Drug: COVID-19 vaccination
Normalized name: COVID-19 VACCINE ADENOVIRUS-26
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID-19 vaccination with 3+ doses
Study: 37365583
Drug: LNA-i-miR-221 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNA-i-miR-221 (5 mg/kg, 30-min IV infusion on 4 consecutive days)
Study: 37365596
Drug: Pyrotinib 400
Normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrotinib 400 mg daily plus letrozole 2.5 mg daily
Study: 37365608
Drug: Lp(a) ≥
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lp(a) ≥ 50 mg/dL in DM group
Study: 37365608
Drug: Lp(a) <
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lp(a) < 10 mg/dL in DM group
Study: 37365608
Drug: Lp(a) ≥
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lp(a) ≥ 50 mg/dL in nonDM group
Study: 37365608
Drug: Lp(a) <
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lp(a) < 30 mg/dL in nonDM group
Study: 37365608
Drug: DM with
Normalized name: Novahistex DM with Decongestant
DrugBank: Pseudoephedrine (DB00852)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DM with Lp(a) < 30 mg/dL
Study: 37365608
Drug: DM with
Normalized name: Novahistex DM with Decongestant
DrugBank: Pseudoephedrine (DB00852)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DM with Lp(a) ≥ 30 mg/dL
Study: 37365618
Drug: Empagliflozin 25
Normalized name: empagliflozin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 25 mg daily initiated at least 15 days before PCI and maintained until the end of follow-up.
Study: 37365656
Drug: AAC +
Normalized name: Acetylsalicylic acid plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAC + nicotine replacement therapy (NRT)
Study: 37365665
Drug: Endoscopic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic treatment (EBD/SEMS)
Study: 37365881
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptives (COCs) containing drospirenone and ethinylestradiol (EE)
Study: 38858523
Drug: Retatrutide 1
Normalized name: Retatrutide
DrugBank: Retatrutide (DB18993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retatrutide 1 mg
Study: 37366315
Drug: Retatrutide 4
Normalized name: Retatrutide
DrugBank: Retatrutide (DB18993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retatrutide 4 mg (combined initial doses of 2 mg and 4 mg)
Study: 37366315
Drug: Retatrutide 8
Normalized name: Retatrutide
DrugBank: Retatrutide (DB18993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retatrutide 8 mg (combined initial doses of 2 mg and 4 mg)
Study: 37366315
Drug: Retatrutide 12
Normalized name: Retatrutide
DrugBank: Retatrutide (DB18993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retatrutide 12 mg (initial dose of 2 mg)
Study: 37366480
Drug: CPAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP treatment for one year
Study: 37366590
Drug: TV-45070, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: TV-45070, a topical semiselective sodium 1.7 channel (Nav1.7) blocker
Study: 37366614
Drug: Cefepime 2000
Normalized name: cefepime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime 2000 mg by 30-min intravenous infusions every 8 to 24 hours
Study: 37366668
Drug: Silver Diamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silver Diamine Fluoride (SDF) therapy with immediate rinsing (Group A)
Study: 37366668
Drug: Silver Diamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silver Diamine Fluoride (SDF) therapy with no rinsing for 30 min (Group B)
Study: 37366919
Drug: Burden of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Burden of Therapy (BOTh) intervention
Study: 37367978
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAPT): 300 mg clopidogrel on the first day followed by 75 mg daily for 12 days, 100 mg aspirin on the first day followed by 100 mg daily for 12 days, and guideline-based antiplatelet treatment until 90 days.